Eisai Invests in Development of Personalized Cancer Rx via Stake in Biotech Startup

"H3 Biomedicine is an independent entity that will have the scientific freedom to choose and follow targets it identifies using genomic insights and modern chemistry, coupled with a disciplined approach to drug discovery and development," an Eisai spokesperson told PGx Reporter.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories